Comparable stake leader
FMR LLC
SEC ownership of Atea Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001593899.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- AVIR on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001593899
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Atea Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
Jean-Pierre Sommadossi
10%
BML Investment Partners, L.P.
9.9%
BlackRock, Inc.
7.1%
Bradley L. Radoff
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
15%
|
$68,238,907
11,950,772 shares
|
+$16,302,575 | 31 Mar 2026 |
| Jean-Pierre Sommadossi |
13D/G
3/4/5
President, CEO, and Chairman, Director
|
10%
|
$26,185,536
8,876,453 shares
|
$0 | 31 Mar 2025 |
| BML Investment Partners, L.P. |
13D/G
Leonard Braden Michael
|
9.9%
|
$27,881,700
7,810,000 shares
|
+$2,119,466 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.1%
from 13D/G
|
$45,382,652
8,435,437 shares
|
— | 31 Mar 2026 |
| Bradley L. Radoff |
13D/G
Radoff Bradley Louis
|
4%
|
$9,971,295
3,380,100 shares
|
+$811,250 | 16 Apr 2025 |
| EcoR1 Capital, LLC |
13D/G
|
4%
|
$9,857,876
3,341,653 shares
|
$0 | 31 Dec 2024 |
| Andrea Corcoran |
3/4/5
Chief Financial Officer, Executive Vice President, Legal and Secretary
|
1%
|
$3,449,970
823,576 shares
mixed-class rows
|
— | 11 Mar 2026 |
| BML Capital Management, LLC |
13F
Company
|
8.9%
|
$37,975,575
7,058,657 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$25,446.
Buys
$25,446
Insiders: 1
Sells
$0
Insiders: 0
Net
+$25,446
Shares: +6,100
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 6,100
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 6,100 | 0 | $25,446 | $0 | +$25,446 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Atea Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Jean-Pierre Sommadossi
Net 12M change
+$25,446
Latest report
18 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jean-Pierre Sommadossi | President, CEO, and Chairman, Director | $22,198,343 | Mixed | 31 Jan 2026 | ||
| Andrea Corcoran | Chief Financial Officer, Executive Vice President, Legal and Secretary | $3,449,970 | Mixed | 11 Mar 2026 | ||
| Franklin M. Berger | Director | $2,987,363 | Mixed | 18 Jun 2026 | ||
| Bruno Lucidi | Director | $869,005 | Mixed | 18 Jun 2026 | ||
| Bruce Polsky | Director | $789,856 | Mixed | 18 Jun 2026 | ||
| Polly A. Murphy | Director | $773,388 | +$25,446 | +3.4% | Mixed | 18 Jun 2026 |
| John Vavricka | Chief Commercial Officer | $671,526 | Mixed | 31 Jan 2026 | ||
| Barbara Gayle Duncan | Director | $600,005 | Mixed | 18 Jun 2026 | ||
| Jerome M. Adams | Director | $600,005 | Mixed | 18 Jun 2026 | ||
| Janet Mj Hammond | Chief Development Officer | $575,724 | Mixed | 31 Jan 2026 | ||
| Maria Arantxa Horga | Chief Medical Officer | $437,239 | Mixed | 31 Jan 2026 | ||
| Wayne Foster | EVP, Chief Accounting Officer | $363,245 | Mixed | 31 Jan 2026 | ||
| Arthur S. Kirsch | Director | $139,873 | Mixed | 18 Jun 2026 | ||
| Howard Berman | Director | Mixed | 18 Jun 2026 |
Recent insider transactions for Atea Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Bruno Lucidi | AVIR | Common Stock | Options Exercise | 26.2% | 29,600 | 142,350 | 18 Jun 2026 | Direct | ||
| Bruno Lucidi | AVIR | Stock Option (Right to Buy) | Award | 37,700 | 37,700 | 18 Jun 2026 | Direct | |||
| Bruno Lucidi | AVIR | Restricted Stock Units | Award | 26,700 | 26,700 | 18 Jun 2026 | Direct | |||
| Bruno Lucidi | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 18 Jun 2026 | Direct | ||
| Franklin M. Berger | AVIR | Common Stock | Options Exercise | 5.84% | 29,600 | 536,097 | 18 Jun 2026 | Direct | ||
| Franklin M. Berger | AVIR | Stock Option (Right to Buy) | Award | 37,700 | 37,700 | 18 Jun 2026 | Direct | |||
| Franklin M. Berger | AVIR | Restricted Stock Units | Award | 26,700 | 26,700 | 18 Jun 2026 | Direct | |||
| Franklin M. Berger | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 18 Jun 2026 | Direct | ||
| Howard Berman | AVIR | Stock Option (Right to Buy) | Award | 37,700 | 37,700 | 18 Jun 2026 | Direct | |||
| Howard Berman | AVIR | Restricted Stock Units | Award | 26,700 | 26,700 | 18 Jun 2026 | Direct | |||
| Barbara Gayle Duncan | AVIR | Common Stock | Options Exercise | 47.2% | 29,600 | 92,350 | 18 Jun 2026 | Direct | ||
| Barbara Gayle Duncan | AVIR | Stock Option (Right to Buy) | Award | 37,700 | 37,700 | 18 Jun 2026 | Direct | |||
| Barbara Gayle Duncan | AVIR | Restricted Stock Units | Award | 26,700 | 26,700 | 18 Jun 2026 | Direct | |||
| Barbara Gayle Duncan | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 18 Jun 2026 | Direct | ||
| Bruce Polsky | AVIR | Common Stock | Options Exercise | 31.1% | 29,600 | 124,806 | 18 Jun 2026 | Direct | ||
| Bruce Polsky | AVIR | Stock Option (Right to Buy) | Award | 37,700 | 37,700 | 18 Jun 2026 | Direct | |||
| Bruce Polsky | AVIR | Restricted Stock Units | Award | 26,700 | 26,700 | 18 Jun 2026 | Direct | |||
| Bruce Polsky | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 18 Jun 2026 | Direct | ||
| Polly A. Murphy | AVIR | Common Stock | Options Exercise | 32.1% | 29,600 | 121,745 | 18 Jun 2026 | Direct | ||
| Polly A. Murphy | AVIR | Stock Option (Right to Buy) | Award | 37,700 | 37,700 | 18 Jun 2026 | Direct | |||
| Polly A. Murphy | AVIR | Restricted Stock Units | Award | 26,700 | 26,700 | 18 Jun 2026 | Direct | |||
| Polly A. Murphy | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 18 Jun 2026 | Direct | ||
| Jerome M. Adams | AVIR | Common Stock | Options Exercise | 47.2% | 29,600 | 92,350 | 18 Jun 2026 | Direct | ||
| Jerome M. Adams | AVIR | Stock Option (Right to Buy) | Award | 37,700 | 37,700 | 18 Jun 2026 | Direct | |||
| Jerome M. Adams | AVIR | Restricted Stock Units | Award | 26,700 | 26,700 | 18 Jun 2026 | Direct | |||
| Jerome M. Adams | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 18 Jun 2026 | Direct | ||
| Arthur S. Kirsch | AVIR | Stock Option (Right to Buy) | Award | 37,700 | 37,700 | 18 Jun 2026 | Direct | |||
| Arthur S. Kirsch | AVIR | Restricted Stock Units | Award | 26,700 | 26,700 | 18 Jun 2026 | Direct | |||
| Polly A. Murphy | AVIR | Common Stock | Purchase | 7.09% | $25,446 | $4.17 | 6,100 | 92,145 | 18 May 2026 | Direct |
| Andrea Corcoran | AVIR | Common Stock | Options Exercise | 7.86% | 60,000 | 823,576 | 11 Mar 2026 | Direct | ||
| Andrea Corcoran | AVIR | Stock Option (Right to Buy) | Options Exercise | 60,000 | 0 | 11 Mar 2026 | Direct | |||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Options Exercise | 64.1% | 300,000 | 767,830 | 03 Feb 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Stock Option (Right to Buy) | Options Exercise | -100% | -300,000 | 0 | 03 Feb 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Common Stock | Tax liability | -14.3% | -16,073 | 96,086 | 31 Jan 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Common Stock | Options Exercise | 84.2% | 51,283 | 112,159 | 31 Jan 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Stock Option (Right to Buy) | Award | 173,500 | 173,500 | 31 Jan 2026 | Direct | |||
| Maria Arantxa Horga | AVIR | Restricted Stock Units | Options Exercise | -100% | -51,283 | 0 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Common Stock | Tax liability | -12.3% | -11,570 | 82,594 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Common Stock | Options Exercise | 80.8% | 42,083 | 94,164 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Stock Option (Right to Buy) | Award | 119,520 | 119,520 | 31 Jan 2026 | Direct | |||
| John Vavricka | AVIR | Restricted Stock Units | Options Exercise | -100% | -42,083 | 0 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Common Stock | Tax liability | -9.97% | -14,136 | 127,665 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Common Stock | Options Exercise | 69.3% | 58,050 | 141,801 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Stock Option (Right to Buy) | Award | 177,000 | 177,000 | 31 Jan 2026 | Direct | |||
| Janet Mj Hammond | AVIR | Restricted Stock Units | Options Exercise | -100% | -58,050 | 0 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Common Stock | Tax liability | -13.3% | -12,132 | 79,329 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Common Stock | Options Exercise | 82.4% | 41,333 | 91,461 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Stock Option (Right to Buy) | Award | 108,000 | 108,000 | 31 Jan 2026 | Direct | |||
| Wayne Foster | AVIR | Restricted Stock Units | Options Exercise | -100% | -41,333 | 0 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Common Stock | Tax liability | -2.07% | -16,104 | 763,576 | 31 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.